TriSalus Life Sciences (TLSI) EBT (2021 - 2026)

TriSalus Life Sciences has reported EBT for 6 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 114.88% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$27.3 million (changed 0.37% YoY), and the FY2025 full-year result was -$39.2 million, down 30.56% from the prior year.
• EBT for Q1 2026 stood at $1.5 million, up from -$9.8 million in the prior quarter.
• The five-year high for EBT was $2.8 million in Q1 2022, with the low at -$35.6 million in Q4 2023.
• Historically, EBT has averaged -$9.0 million across 5 years, with a median of -$8.3 million in 2025.
• The largest YoY upside for EBT was 1137.69% in 2022 against a maximum downside of 878.25% in 2022.
• TriSalus Life Sciences' EBT stood at -$22.5 million in 2022, then tumbled by 58.14% to -$35.6 million in 2023, then surged by 71.63% to -$10.1 million in 2024, then advanced by 3.52% to -$9.8 million in 2025, then soared by 115.82% to $1.5 million in 2026.
• The last three EBT figures came in at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$10.8 million (Q3 2025), per Business Quant data.